Predicting Isoniazid Resistance in Mycobacterium tuberculosis Complex in New York State using Whole Genome Sequencing

Abstract

Isoniazid (INH) is a critical antibiotic used worldwide for treatment and prophylaxis of tuberculosis. Drug resistance (DR) to INH is the single most common type of DR, mediated by multiple genes/loci including katG, inhA, mabA, mabA-inhA and the oxyR-ahpC intergenic region. Over the course of 6 years, we performed a 2-phase study of 3,696 Mycobacterium tuberculosis complex (MTBC) strains aiming to determine the molecular basis of INH resistance and assess whole genome sequencing (WGS) for predicting resistance. In phase 1, we performed a side-by-side study including 1,767 strains with paired phenotypic drug susceptibility testing (DST) and genotypic DST. We found WGS capable of accurately predicting INH resistance with sensitivity of 90.3%, and specificity of 99.8%. The negative predictive value of WGS for INH susceptibility was 98.8%. Based on these findings, we developed a molecular testing algorithm where phenotypic DST was reduced and applied this new testing algorithm in phase 2 to 1,929 MTBC strains, resulting in streamlined testing, reduced cost and decreasing turnaround time (TAT). The prevalence of INH resistance among MTBC strains in New York was found to be 10.2%. Of the 3,696 isolates tested, 337 were predicted INH resistant by WGS. Of 41 additional strains exhibiting phenotypic INH resistance, 38 were found to have mutations in genes known to be associated with INH resistance. This study demonstrates the utility of WGS as a molecular tool for predicting INH DR and shows that the vast majority of INH resistance in MTBC has a molecular basis in known resistance loci.